The menopausal transition involves profound shifts in oestrogen and progesterone levels, triggering vasomotor symptoms such as hot flushes and night sweats, alongside mood changes, sleep disruption, and vaginal dryness. Whilst conventional hormone replacement therapy addresses many symptoms, some women seek or require alternatives. Regenerative medicine approaches—particularly placental-derived exosomes and mesenchymal stem cells—are being studied as potential supplements to traditional management, with interest centred on whether these agents might support natural hormonal regulation and tissue repair. Current research remains exploratory, focused on mechanisms rather than clinical equivalence to established treatments.
Approximately 10 registered trials are investigating stem cell and exosome therapies for menopause-related symptoms. A 2023 small-scale study of placental MSCs reported subjective improvement in hot flush frequency in 70% of participants over 12 weeks, though follow-up assessments remain limited. Exosome trials have focused on anti-inflammatory signalling rather than direct hormone replacement. No large multicentre randomised controlled trials have yet demonstrated safety or efficacy comparable to hormone therapy, and recruitment for new menopause-focused stem cell studies has stalled. Evidence remains preliminary and largely mechanistic.
Regenerative treatments for menopausal symptoms typically range from £3,000 to £8,000 per course abroad, with some clinics offering packages combining exosomes and MSCs. UK private clinics offering stem cell-adjacent treatments charge upwards of £2,500 for initial consultations and injections. Importantly, these interventions sit outside standard NHS coverage and are not regulated under established pharmaceutical frameworks. Costs reflect research and manufacturing rather than proven clinical advantage over hormone therapy, which may cost £30–£100 annually via prescription.
Cell therapy for Menopause & Hormonal Health is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Menopause & Hormonal Health programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Menopause & Hormonal Health overview · Menopause & Hormonal Health cost →
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită